51 assays · 0 complete · 47 partly written · 4 not yet written
Assays
The assay menu. Each row is one way of measuring something; sort and filter to choose one at any stage of the screening cascade.
-
Affinity purification mass spectrometry (AP-MS)AP-MS hooks one tagged protein out of broken-open cells, washes, and uses a mass spectrometer to count which other proteins came along, giving a statistical statement of co-complex membership rather than of direct binding. Which proteins stay with this bait, in this cell type and under this wash, in amounts above background? Contact: in BioPlex 3.0, only 32% of edges that fall within 309 structures were direct contacts. in-vitro-biochemical cell-based target-id medium 850 to 1,360 USD per sample, pulldown plus measurement no partly written
What it is. AP-MS captures one tagged protein from lysed cells with its partners, then identifies what stayed attached with a mass spectrometer. A score compares each protein's count with background. It tells you who sat in the same assembly in that cell type under that wash, not who touches whom.
-
Animal modelsWhole animals, most often mouse, used to test safety and efficacy before humans; they keep a body and an immune system and lose human-specific biology. not yet written not yet written in-vivo preclinical not yet written not yet written not yet written partly written
The short answer. Animals give a whole body with circulation and immunity, but translation to humans is partial and no single rate describes it. See concepts/animal-to-human-translation.
-
ATAC-seqATAC-seq reads how physically open the DNA is by letting a transposase insert sequencing adapters into native chromatin, mostly where DNA is not tightly occupied. Which stretches of the genome are accessible to a probe in a population of nuclei: it reads accessibility, not any named protein. An accessible region is not shown to be bound by a factor or to drive a gene. cell-based not yet written not yet written not yet written not yet written partly written
What it measures. Tn5 inserts adapters mainly where DNA is exposed, so reads mark open chromatin. It needs only 500 to 50,000 cells, against about 50 million cells for DNase-seq as stated by the original paper.
-
Bisulfite sequencing (WGBS and targeted)Bisulfite sequencing turns the invisible methyl tag on cytosine into a visible letter change: unmethylated C is converted to U and reads as T, while 5-methylcytosine stays C. Which cytosines, at single-base resolution, were methylated in the DNA that was put in? It reports a fraction across the molecules sequenced at each site. in-vitro-biochemical not yet written not yet written not yet written not yet written partly written
How it works. A sequencer cannot see a methyl group, because 5-methylcytosine pairs with G exactly like plain C. Bisulfite chemistry changes that: it turns unmethylated cytosine into uracil, which PCR copies as T, while methylated cytosine stays C. After sequencing, a C means methylated and a T means not, counted over many reads.
-
Caco-2 permeability assayA human colon-cancer cell line grown as a tight sheet on a filter is dosed on one side and the drug appearing on the other side gives apparent permeability and an efflux ratio. Whether and how fast a compound crosses a gut-like cell sheet, and whether a pump pushes it back (efflux ratio). Transporters the cells lack and the paracellular route; hydrophilic transporter substrates such as amiloride, cephalexin, levodopa and zidovudine were discussed as false positives across PAMPA and Caco-2. cell-based lead-optimisation preclinical not yet written not yet written not yet written partly written
-
ChIP-seqChIP-seq finds where a chosen protein or histone mark sits on the genome by pulling the DNA bound to it out of fragmented chromatin with an antibody and sequencing it. Where, across a population of cells, a protein or histone modification is enriched on the genome. It does not show that a factor is functionally acting at a peak, which cells carry the signal (it averages over the population), or how many molecules are bound. cell-based not yet written not yet written not yet written not yet written partly written
What it answers and what it cannot see. ChIP-seq maps where a chosen protein or mark is enriched, averaged over many cells. It cannot show that the signal is binding rather than assay artefact, that the site is functional, or what any one cell looks like.
-
Co-immunoprecipitation (co-IP) and pull-downCo-IP captures one protein from a gently lysed cell with an antibody or tag and uses a western blot to ask whether a second named protein came along, so a positive means the two stayed together through capture and washing. Do protein A and protein B co-purify from a lysate made this way? Direct contact (a third protein can bridge), where in the cell they meet, how tightly, how many copies, or how fast. in-vitro-biochemical target-id low not yet written no partly written
What it is. A co-IP fishes one protein out of a gently broken-open cell and checks whether another protein came along. The check is a western blot. A positive means the two stayed together through washing; it does not say they touch or where.
-
Crosslinking mass spectrometry (XL-MS)Crosslinking mass spectrometry glues together protein residues that sit within reach of a chemical linker of known length, then uses a mass spectrometer to read which two residues were joined. Which two residues, in which proteins, were within reach of a linker of known length? Binding, affinity or kinetics. in-vitro-biochemical cell-based target-id low 420 to 630 USD per purified-complex sample (3 to 5 injections) no partly written
The short version. XL-MS glues two residues together with a molecule of known length, then reads which two got glued. A hit says these two residues were within reach, about 30 A between alpha-carbons for BS3. The hard part is trust: a hit needs two correct peptides, so errors multiply and grow as spectra are merged into residue pairs (5% became 8.4% in one yeast dataset).
-
CUT&RUNCUT&RUN maps where a protein or histone mark sits by letting an antibody guide a nuclease to cut the DNA next to it inside permeabilised nuclei, then sequencing the released pieces. Where a chosen protein or mark is located, at high resolution, without crosslinking. A peak is not proof of binding or function. cell-based not yet written not yet written not yet written not yet written partly written
How it works. An antibody finds its target inside permeabilised nuclei; a nuclease tethered to the antibody cuts DNA around it and the pieces are released and sequenced. Because the whole genome is not fragmented, background is low.
-
CUT&TagCUT&Tag maps a protein or histone mark by tethering the Tn5 transposase to an antibody, so adapters are inserted only next to the target in permeabilised cells. Where a protein or histone mark is enriched, from very small samples and single cells. A peak does not prove the mark is there. cell-based not yet written not yet written not yet written not yet written partly written
What it answers and what it cannot see. It maps antibody targets from tiny samples. The same enzyme that gives its low background also has a habit of inserting at open DNA, so a mark peak can be partly an accessibility peak. Check against IgG and an accessibility track before reading a peak as a mark.
-
CYP inhibition screen To write it: What does an in vitro CYP inhibition screen measure, what is it used to predict, and where has it failed? No limitation was found in opened sources. not yet written
To write this, these must be answered:
- What does an in vitro CYP inhibition screen measure, what is it used to predict, and where has it failed? No limitation was found in opened sources.
-
DNA methylation array (Illumina EPIC)A methylation array measures DNA methylation only at a fixed, predefined set of CpG sites chosen by the manufacturer, rather than across the whole genome. What is the methylation level at each of a predefined list of CpG sites in this sample? Any CpG that is not among its predefined probes. in-vitro-biochemical not yet written not yet written not yet written not yet written partly written
What it is. The Illumina EPIC array was one of the four methods compared in a 2025 study of genome-wide methylation profiling, alongside whole-genome bisulfite sequencing, EM-seq and Oxford Nanopore sequencing. Unlike the sequencing methods it works from predefined sites, so it cannot discover methylation outside them.
-
DNA-encoded library screening To write it: What question does it answer, what is physically measured, what can it not see, what does it cost (a range, with basis and date), where in the cascade is it used, and which real campaigns used it? not yet written
To write this, these must be answered:
- What question does it answer, what is physically measured, what can it not see, what does it cost (a range, with basis and date), where in the cascade is it used, and which real campaigns used it?
- What did people do before and after it arrived, and where did the capital go?
-
Dose-response assayA dose-response assay runs the same measurement at a series of compound concentrations and fits a curve, so potency and the shape of the effect become numbers. How potent is this compound in this assay, and does its effect rise smoothly with dose? Affinity or mechanism (IC50 shifts with substrate and enzyme concentration); whether the effect is on target (an aggregator or a luciferase inhibitor can give a clean curve); and comparability across labs and days (in a… in-vitro-biochemical cell-based hit-discovery hit-to-lead medium 31 to 58 USD per compound, 8-point dose-response in duplicate no partly written
In short. A dose-response curve is a few numbers pulled from a sigmoid: bottom, top, midpoint (IC50 or EC50) and slope. The midpoint is a potency under that experiment's conditions. It is not an affinity. The fit also fails quietly: partial curves, steep slopes, bell shapes and cell division rate all distort the number without any error message.
His question: why does controllable dosage matter?. He said: "You maybe do dose response. Now you have how potent the compound is, and you're looking for something that you can control the dosage of to get a desired effect, because actually, I'm not sure why."
-
Enzymatic methyl-seq (EM-seq)EM-seq reads DNA methylation as a C-versus-T letter change like bisulfite, but with enzymes that first protect methylated cytosine and then deaminate the rest, instead of harsh chemistry. The same question as bisulfite sequencing: which cytosines were methylated, per CpG, at single-base resolution, as a fraction of reads. It reports 5mC and 5hmC together, as bisulfite does; the authors state an add-on step is needed to separate them. in-vitro-biochemical not yet written not yet written not yet written not yet written partly written
How it works. EM-seq protects first, then converts. One set of enzymes (TET2 and T4-BGT) shields methylated and hydroxymethylated cytosine. A second enzyme, APOBEC3A, then turns every unshielded cytosine into uracil, read as T. The result looks like a bisulfite run, without the harsh chemistry that destroys DNA.
Whose evidence this is. The main EM-seq paper was written by employees of New England Biolabs, the company that sells the kit, and the study was funded by NEB, according to its competing-interest statement. Its performance claims are therefore vendor-authored. The independent evidence read for this record is one abstract of a head-to-head comparison.
-
Enzyme activity assayAn enzyme activity assay measures how fast a purified enzyme makes product, then asks how a compound slows that rate under conditions the experimenter chose. Does this molecule change the catalytic rate of this protein, here, by this mechanism? Whether the compound enters or survives in a cell, or whether the target matters in a cell; where it binds (mode of inhibition is a pattern in rates, not a structure); true affinity from a single-substrate-level IC50;… in-vitro-biochemical hit-discovery hit-to-lead high 0.28 to 0.54 USD per compound, single-concentration primary biochemical screen no partly written
In short. An enzyme assay does not measure binding. It measures how fast product appears, then asks how a compound slows that. A hit is a slower rate, under conditions you chose. IC50 moves with substrate concentration; Ki does not. A hit is a statement about a rate, and the conditions are part of the result.
His line: inhibition means an enzyme assay. He said: "If it is inhibition, then maybe you have an enzyme assay, and if it is activation, maybe you have something else, right? You have some pipeline."
-
Genetic interaction and epistasis screensA genetic interaction screen breaks two genes at once and asks whether the double mutant behaves differently from what the two single mutants predict, which reveals functional relationships without touching any protein. Do these two genes work in the same pathway or complex, or in parallel routes to the same essential job? Contact, direction, mechanism, or whether the relation holds in another cell type. cell-based target-id ultra-high not yet written no partly written
The short version. A genetic interaction is a surprise: you break gene A and gene B together and the double mutant grows differently from what the two single mutants predict. The gap is the epsilon score. Genes with similar rows of scores work in the same pathway or complex, but this measures functional relatedness, never contact: only 30 of 4,039 genetically interacting yeast pairs encoded physically interacting proteins.
-
Genome-wide association study (GWAS)A GWAS compares the frequency of many common variants between large groups of people (cases and controls, or high and low values of a trait) to flag regions of the genome associated with the trait. Which common variants are more frequent in people with a trait than in people without it. Which variant is causal, which gene it acts on, and in which direction. clinical in-silico target-id high not yet written no partly written
What a GWAS is and is not. A GWAS compares many people, variant by variant. Analysing one patient's variants against the reference and population databases is a different activity; his sentence runs the two together.
-
Genome-wide CRISPR dependency screenA pooled knockout screen that asks which genes a cell line needs to grow, scored as a per-gene fitness effect. Which genes, when knocked out, make a cell line grow worse. Whether a gene can be drugged, and whether the dependency holds in a patient. cell-based in-silico target-id not yet written not yet written not yet written partly written
What it gives and what it does not. Guides are counted before and after growth; a model turns the drop in guides into a per-gene fitness score. A score says the gene mattered in that cell line under that medium, not that a drug against it would work in a child.
-
H&E stainingA stain that colours nuclei and cytoplasm so a pathologist can read tissue architecture on a thin section; the reading is human and the slice is two-dimensional. What the cells and tissue architecture look like in one thin section, as read by a pathologist. Molecules, unless paired with another assay; three-dimensional organ structure beyond the section. ex-vivo clinical not yet written not yet written not yet written not yet written partly written
His statement (his words). He said: "H&E helps, but it's still not at the organ level."
The sourced account in short. No opened source measures what organ-level information a slide loses. What is measured is the reading: 115 pathologists agreed with a consensus reference in 75.3% of 6,900 breast biopsy interpretations.
-
Hepatocyte stability assayWhole liver cells are incubated with a compound and parent depletion gives intrinsic clearance, with uptake transporters and conjugation enzymes present. How fast intact liver cells remove the compound, including uptake and conjugation, so human hepatic clearance can be estimated. Anything outside the liver, and the whole-liver behaviour the stirred-tank equation hides; standard assays predict poorly for low-turnover compounds (one vendor poster, overview only). cell-based lead-optimisation preclinical not yet written not yet written not yet written partly written
-
Hi-CHi-C finds which parts of the genome sit close together in the nucleus by gluing neighbouring DNA pieces together and sequencing the joins. How often two genomic loci are found in contact, across a population of cells: a matrix of interaction frequencies that reveals compartments, domains and loops. Contact frequency is not regulation and the map is a population average. cell-based not yet written not yet written not yet written not yet written partly written
What it answers and what it cannot see. Hi-C maps genome-wide contact frequencies between loci. It cannot show distances in one cell, change over time, or that a contact causes any expression change.
-
High-content imaging and morphological profilingPhotograph treated cells stained with several dyes and turn each cell into a long list of measurements, so compounds can be compared by how the cells look rather than by one pre-chosen readout. Which known compounds or gene perturbations does this treatment make the cells resemble, and does the treated cell look more like disease or like health? It does not identify a target or mechanism: it reports similarity to annotated compounds, and a match is a hypothesis. cell-based hit-discovery hit-to-lead high from 0.26 USD per well, stain reagents only yes partly written
In his words: what imaging adds. He said: "You just may want to understand the morphologies of certain cells treated with and without a compound to understand how it affects things. I don't really understand the purpose of this, like how it differs."
How it differs from a viability readout. Your description (cells treated with and without a compound, then look at their shape) is right. The difference is that a viability screen gives one number per well, chosen in advance. Imaging stains many cell parts and measures about 1,500 features per cell, so each compound gets a fingerprint and you can ask which known drugs it resembles. The question is not fixed beforehand.
-
Immortalised cell linesCells that grow indefinitely in culture and serve as cheap, uniform stand-ins for tissues and tumours, at the cost of identity, drift and missing context. How a cultured cell type responds to a perturbation, as a stand-in for the tissue it came from. Behaviour in an intact tissue with immune cells, circulation and stroma. cell-based not yet written not yet written not yet written not yet written partly written
The short answer. Cell lines are cheap and scalable, but some are not the cells on the label and many drift between labs. They are models of a tissue, not the tissue.
-
Immunofluorescence and protein tagging To write it: What question does it answer, what is physically measured, what can it not see, what does it cost (a range, with basis and date), where in the cascade is it used, and which real campaigns used it? not yet written
To write this, these must be answered:
- What question does it answer, what is physically measured, what can it not see, what does it cost (a range, with basis and date), where in the cascade is it used, and which real campaigns used it?
- How is a protein tagged to see whether it is degraded, or one part marked to see whether it is bound?
-
Isothermal titration calorimetry (ITC)Isothermal titration calorimetry measures the heat released or absorbed as one purified binding partner is titrated into another, giving affinity and stoichiometry without labels or surface attachment. How tightly do two purified molecules bind (Kd), in what ratio (stoichiometry), and with what heat (enthalpy), measured in free solution with no label and nothing stuck to a surface? Kinetics and context. in-vitro-biochemical hit-discovery hit-to-lead low 300 to 600 USD per titration at a university core (first sample with optimisation $600; each further sample $300) no partly written
The short version. ITC watches the heat of binding as one partner is dripped into the other. It gives Kd and stoichiometry from the same curve, with nothing labelled and nothing stuck to a surface. It needs more purified protein than most binding assays, works best in a window where c = [M]/Kd is between 1 and 500, and gives no rates.
-
Live imaging of transcription at one gene (MS2 and PP7 loops)Stem-loops engineered into a gene bind fluorescent coat protein as the RNA is made, so one gene's activity can be watched in a living cell. When a single gene fires, how many RNAs each burst makes, and how long polymerases take along a stretch of gene. A single moving polymerase. cell-based not yet written not yet written not yet written not yet written partly written
-
Long-read RNA sequencing (nanopore, PacBio)Reads whole RNA molecules, so which exons sit together on one transcript can be seen directly. Which full-length isoforms exist, where short reads can only count junctions. Accuracy and annotation. cell-based not yet written not yet written not yet written not yet written partly written
-
Luminescent cell viability assay (CellTiter-Glo)A one-reagent plate assay that breaks open the cells and uses a luciferase enzyme to turn the ATP in the well into light, read as a proxy for how many healthy cells are left. How much ATP is left in the well after treatment, which the vendor premise treats as a proxy for how many healthy cells remain. It cannot separate dead cells from cells that have stopped dividing, cannot say which mechanism acted, cannot show whether a protein is gone, and says nothing about single cells. cell-based hit-discovery hit-to-lead high not yet written no partly written
In his words: what it tells you. He said: "I've seen high-throughput screening done for Cell Titer-Glo, which just tells you if a cell is alive or not."
What it actually tells you. Your format is right: cells, compound, add reagent, read. The gap is what 'alive' means to the readout. CellTiter-Glo measures ATP, not life, and 'ATP is proportional to cell number' is the vendor's premise, not a law. In one study gemcitabine cut cell counts about 74% while ATP fell under 20%. So it tells you how much ATP is in the well.
-
Mass-spectrometry proteomicsProteins are cut into peptides, weighed in a mass spectrometer and identified by matching to a database; the protein list is an inference from peptides. Which proteins are present in a sample and how their abundance compares, inferred from peptides. Proteoforms, very-low-abundance proteins, and whether a peptide truly belongs to the protein it is assigned to. cell-based ex-vivo not yet written not yet written not yet written not yet written partly written
The short answer. The instrument counts peptide ions. Software names peptides by matching to a database or library, and then guesses which proteins they came from, so "N proteins identified" is the output of a chain, not a head-count.
-
Metabolic labelling for RNA and protein turnover (BRIC-seq, 4sU, dynamic SILAC)Label new RNA or protein and follow what remains or appears, to get half-lives without blocking transcription or translation. How long RNAs and proteins last in a cell, and how fast new ones are made. Degradation separate from dilution by division (needs non-dividing cells or a correction), and transcripts below an abundance cut-off (BRIC-seq here used RPKM above 1). cell-based not yet written not yet written not yet written not yet written partly written
-
Microsomal stability assayLiver microsomes, membrane fragments rich in CYP enzymes, are incubated with a compound and the disappearance of the parent is used to estimate intrinsic clearance. How fast liver cytochrome P450 enzymes remove the compound, as intrinsic clearance, so human clearance can be estimated by scaling. Uptake into cells, bile, and anything not in the membrane fragment; the vendor page lists hepatocytes and S9 as alternatives. in-vitro-biochemical lead-optimisation preclinical medium not yet written not yet written partly written
-
N-terminal proteomics (COFRADIC)Mass spectrometry that enriches each protein's first peptide so the real start of the protein, not the predicted one, is read. Where in the sequence proteins actually begin, and so which N-terminal versions of a protein exist in a cell. Low-abundance forms and isoforms outside the database. cell-based not yet written not yet written not yet written not yet written partly written
-
Nascent-RNA sequencing (GRO-seq, PRO-seq, NET-seq, mNET-seq, TT-seq)Methods that read where RNA polymerase II is engaged on DNA, or what it made in the last minutes, instead of the accumulated RNA. Where engaged RNA polymerase II sits on the genome, and how much new RNA a gene made in a short window, as opposed to ordinary RNA-seq, which counts RNA that has accumulated. A dwell time. A pausing index is a read-density ratio and not a time. cell-based not yet written not yet written not yet written not yet written partly written
-
Organ-on-chipA microfluidic device culturing human cells under flow and mechanical strain to mimic an organ; the one large validation found is vendor-authored. not yet written not yet written cell-based not yet written not yet written not yet written not yet written partly written
The short answer. A Liver-Chip study flagged most toxic drugs among 27 blinded drugs, but it was written mostly by the chip maker's employees and no independent replication was found.
-
OrganoidsThree-dimensional cultures grown from stem cells that self-organise into tissue-like structures; they preserve structure and lose the immune system and, mostly, a perfused circulation. How stem-cell-derived tissue-like structures behave under perturbation, as a stand-in for the organ. Whole-body circulation, immune trafficking and inter-organ pharmacokinetics; no opened source shows these in an organoid. cell-based ex-vivo not yet written not yet written not yet written not yet written partly written
His statement (his words). He said: "Yes, organoids will help, but they still don't simulate the circulatory system."
The sourced account in short. Vessels exist in organoids and a kidney organoid on a flow chip has perfusable lumens, but full perfusion otherwise appears after transplant into a mouse, which is the host's circulation. No source shows whole-body circulation.
-
Parallel artificial membrane permeability assayA lipid-soaked artificial membrane is used to measure passive permeability only, without transporters. How fast a compound crosses a lipid membrane by passive diffusion alone. Transporters and paracellular junctions; both PAMPA and Caco-2 were described as deficient in them. in-vitro-biochemical lead-optimisation not yet written not yet written not yet written partly written
-
Plasma protein binding assay To write it: How is the unbound fraction measured (equilibrium dialysis, ultracentrifugation), how accurate is it for highly bound drugs, and what does it predict? not yet written
To write this, these must be answered:
- How is the unbound fraction measured (equilibrium dialysis, ultracentrifugation), how accurate is it for highly bound drugs, and what does it predict?
-
Primary cellsCells taken directly from a donor or tissue and grown for a limited time; they keep donor biology but stop dividing or lose function. not yet written not yet written cell-based ex-vivo not yet written not yet written not yet written not yet written partly written
The short answer. Primary cells keep donor biology that immortalised lines lose, but they are limited in how long they divide and function in culture.
-
Proximity labelling (BioID, TurboID, APEX)Proximity labelling fuses an enzyme to a bait protein in living cells so that it stamps a chemical tag on whatever lies within its reach, giving a neighbourhood list rather than a list of binding partners. Which proteins were within reach of a labelling enzyme fused to this bait, in a living cell, during the labelling window? Binding, direct contact, affinity or stoichiometry. cell-based in-vivo target-id low not yet written no partly written
What it is. Proximity labelling attaches a short-lived chemical stamp to proteins near a bait inside living cells. Tagged proteins are pulled out and identified. The list says who was nearby, not who binds.
-
Reporter gene assayA reporter gene assay puts an easy-to-measure gene, often a luciferase, under a chosen promoter, so a cell's light reports how strongly that switch was turned on, not what your protein does. Does this compound, in a living cell, push a chosen pathway or response element to switch a gene on or off? The activity, abundance or location of the native protein; anything the construct's promoter does not respond to; and which step upstream of the promoter the compound acted on. cell-based hit-discovery hit-to-lead high not yet written not yet written partly written
The short version. A reporter gene assay does not measure your protein. It measures how hard a chosen stretch of DNA drives a stand-in gene whose product gives off light or colour. Amit's guess is right in shape: this is how a cell-based screen can read pathway activity, as opposed to a viability reagent such as CellTiter-Glo, which reads ATP. The best-documented trap is that the reporter enzyme is itself a drug target.
-
Ribosome profiling (Ribo-seq)Sequences the roughly 30-nucleotide pieces of mRNA a ribosome shields from a nuclease, giving where ribosomes sit across the transcriptome. Which parts of which mRNAs ribosomes are on, and with drugs that freeze initiating ribosomes, where translation starts. That a stable, functional protein results. cell-based not yet written not yet written not yet written not yet written partly written
-
RNA-seqRNA sequencing counts short DNA reads made from RNA; everything else, from which gene a read came from to what an abundance means, is inference. Which genes are expressed, and which differ between samples, as read counts of RNA fragments. Absolute RNA copy number, protein level, and the isoform of reads that fit several transcripts. cell-based ex-vivo not yet written not yet written not yet written not yet written partly written
The short answer. RNA-seq counts reads, not RNA molecules. It reproduces relative change between samples far better than absolute level, and its numbers are shaped by library preparation, alignment and normalisation before any biology is read.
-
Selectivity panelA set of related or liability proteins a compound is tested against, to see what else it hits. Besides the target, which of the proteins on this list does the compound bind or inhibit, and how much more weakly? Anything not on the list: proteins outside the family, activity in cells, and toxicity. in-vitro-biochemical hit-to-lead lead-optimisation preclinical not yet written not yet written not yet written partly written
-
Structural evidence of complexes (crystallography and cryo-EM)A structure shows which atoms of two proteins touch in a purified, crystallised or frozen state, which is why it is used as the yardstick for judging other interaction assays, and why its own errors matter. Which atoms of protein A touch which atoms of protein B, and is that contact biological or an artefact of how the sample was prepared? Affinity, kinetics and whether the complex forms in a cell. in-vitro-biochemical target-id hit-to-lead low not yet written no partly written
The short version. A structure is a picture of a purified, often crystallised or frozen, state. It shows which atoms touch, which no other assay shows, and it is the yardstick behind 90% of HuRI pairs in complexes being direct contacts versus 81% for literature pairs and under 50% for complex maps. But the yardstick has its own error: at least 7% to 14% of PDB assembly annotations were estimated wrong.
-
Surface plasmon resonance (SPR)Surface plasmon resonance measures, in real time and without labels, how a compound or protein binds a protein fixed to a gold surface, giving on and off rates as well as affinity. Does this compound physically bind this purified, immobilised protein, and how fast does it go on and come off? Function, and anything in cells. in-vitro-biochemical hit-discovery hit-to-lead medium 260 USD per sample, full service, including 3 replicates no partly written
The short version. SPR does not see the compound. It sees the refractive index within about 300 nm of a gold film rise when mass lands on the immobilised protein. A small molecule is a tiny mass, so every measurement is a fight against bulk-solvent signal. In return it is the one cascade step that gives rates, not just a yes or no.
-
Target engagement in cells (CETSA, NanoBRET)Assays that ask whether a compound reaches and physically binds its intended protein inside living cells, without asking whether the binding does anything. Does the compound reach the intended protein inside a living cell and physically bind it? Function: neither assay shows that binding changes what the protein does. cell-based ex-vivo in-vivo hit-to-lead lead-optimisation medium not yet written no partly written
What target engagement asks. Target engagement asks one narrow question: does the compound physically bind the intended protein inside a living cell? It does not ask whether the binding does anything. CETSA heats cells and sees whether the target survives higher heat when bound. NanoBRET lets the compound push a glowing tracer off a luciferase-tagged target, so light falls as it binds.
-
Western blotA Western blot sorts the proteins in a lysate by size on a gel, moves them to a membrane and uses an antibody to show how much of one protein is there. Is there less (or more) of a protein of this apparent size that this antibody recognises? Why a band shrank: degradation, less transcription, less translation or dead cells all lower it, so degrader papers add proteasome and ligase-dependence experiments. cell-based hit-to-lead lead-optimisation low 175 to 250 USD per assay (unit not stated on the menu) no partly written
The short version. A Western blot asks one narrow question: is there less or more of a protein of this apparent size that this antibody recognises? The number is only as good as the antibody (does it see only the target?) and the signal (is the band inside the range where brighter means more?). Both fail silently, and neither shows in a figure.
-
Whole-exome sequencingWhole-exome sequencing captures and reads the protein-coding regions of the genome, a small share of it, at higher depth than a typical genome. Which coding variants a person carries; the usual first test for a suspected single-gene (Mendelian) disease. Noncoding regions, where most GWAS signal lies, and variants in regions the capture design misses. clinical in-silico target-id not yet written not yet written not yet written partly written
-
Whole-genome sequencingWhole-genome sequencing reads essentially the whole of a person's genome as short reads, which are mapped to a reference and turned into variant calls. Which positions in the whole genome differ from the reference in this person, coding and noncoding, including variants a capture-based exome never targets. Repeats and near-identical gene copies where reads cannot be placed uniquely: a missing variant there can mean could not see. clinical in-silico target-id not yet written 221 USD per 30x human genome (external core rate, batch of 24) not yet written partly written
-
Yeast two-hybrid (Y2H)Yeast two-hybrid asks whether two proteins can touch: each is fused to half of a yeast transcription factor, and if they bind, the halves come together and switch on a reporter gene that lets the yeast grow. Can protein A and protein B physically contact each other, in a yeast nucleus, when each is fused to one half of a transcription factor? Affinity, kinetics and stoichiometry: it gives a yes or no for one construct. cell-based target-id high not yet written no partly written
What it is. Yeast two-hybrid tests whether two proteins can touch. Each is fused to half of a yeast transcription factor. If they bind, the halves reunite and switch on a reporter gene, so the yeast cell grows. It answers a yes or no about contact, not about strength, timing or the human cell.